Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
暂无分享,去创建一个
Jean-David Fumet | S. Ladoire | B. Royer | I. Desmoulins | Antonin Schmitt | D. Mayeur | Courèche Kaderbhaï | Z. Tharin | S. Ilie | A. Hennequin | Siavoshe Ayati | Alexandre Le Marouille | Emma Petit | J. Fumet
[1] Jean-David Fumet,et al. Population Pharmacokinetics of Palbociclib in a Real-World Situation , 2021, Pharmaceuticals.
[2] W. Huisinga,et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs , 2020, European Journal of Clinical Pharmacology.
[3] Haihong Shi,et al. Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function , 2020, Cancer Chemotherapy and Pharmacology.
[4] Y. Sheng,et al. Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer , 2020, Cancer management and research.
[5] M. Spilker,et al. A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor , 2020, Journal of Pharmacokinetics and Pharmacodynamics.
[6] B. Royer,et al. A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma. , 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[7] M. Whyte,et al. Alkaline Phosphatase: Discovery and Naming of Our Favorite Enzyme , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] G. Shapiro,et al. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic‐Pharmacodynamic Modeling and Simulation Approach , 2017, Journal of clinical pharmacology.
[9] H. Iwata,et al. PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients , 2017, Journal of global oncology.
[10] R. Sahoo,et al. Neutropenia due to palbociclib: A word of caution? , 2016, Indian Journal of Medical and Paediatric Oncology.
[11] B. Ramaswamy,et al. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer. , 2015, The Annals of pharmacotherapy.
[12] R. Pazdur,et al. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer , 2015, Clinical Cancer Research.
[13] I. Trocóniz,et al. Semimechanistic Cell-Cycle Type–Based Pharmacokinetic/Pharmacodynamic Model of Chemotherapy-Induced Neutropenic Effects of Diflomotecan under Different Dosing Schedules , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[14] I. Treilleux,et al. [New therapeutical strategies in metastatic hormone-dependent breast cancer]. , 2015, Bulletin du cancer.
[15] Sohita Dhillon. Palbociclib: First Global Approval , 2015, Drugs.
[16] I. Treilleux,et al. [New therapeutical strategies in metastatic hormone-dependent breast cancer]. , 2015, Bulletin du cancer.
[17] Xin Huang,et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.
[18] D. D. Wang,et al. 462PA POPULATION PHARMACOKINETIC (PK) ANALYSIS OF PALBOCICLIB (PD-0332991) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] D. Concordet,et al. Model-Based Approach to Describe G-CSF Effects in Carboplatin-Treated Cancer Patients , 2013, Pharmaceutical Research.
[20] D R Mould,et al. Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods , 2013, CPT: pharmacometrics & systems pharmacology.
[21] K. Flaherty,et al. Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer , 2011, Clinical Cancer Research.
[22] F. Pinguet,et al. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] G. Lyman,et al. Risk models for predicting chemotherapy-induced neutropenia. , 2005, The oncologist.
[24] Mats O Karlsson,et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.